Meghan Campo, MD, David Gerber, MD, Justin F. Gainor, MD, Rebecca S

Slides:

Advertisements

Similar presentations

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors by Lecia V. Sequist, Belinda A. Waltman, Dora Dias-Santagata,

Advertisements

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non–Small Cell Lung Cancers Christos.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification Justin.

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment Tiffany G. Huynh, BA, Vicente Morales-Oyarvide,

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Electronic Updates for JTO Readers

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer Justin F. Gainor, MD, Sai-Hong Ignatius Ou, MD, PhD, Jennifer.

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Vipul Pareek, MD, Mary Welch, MD, Elizabeth Ravera, RN, Richard L

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer Charles M. Rudin, MD, PhD,

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial Kenneth S. Thress, PhD, Vivien.

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Jessica J. Lin, MD, Elizabeth Kennedy, BA, Lecia V

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Jamie A. Saxon, PhD, Lynette M. Sholl, MD, Pasi A. Jänne, MD, PhD

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Lipodermatosclerosis Secondary to Pemetrexed Use

Erratum Journal of Thoracic Oncology

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

ED11.01 Systemic Therapy for Advanced Oncogene-Driven NSCLC

Jessica J. Lin, MD, Ginger Y

A Primer on Health Economic Evaluations in Thoracic Oncology

S768I Mutation in EGFR in Patients with Lung Cancer

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases Hironori Uruga, MD, PhD, Emine Bozkurtlar,

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Jennifer S. Temel, MD, William F. Pirl, MD, Christopher J

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

It’s All in the “Swerve of the Curve”

Phase I Study of Lenalidomide in Solid Tumors

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Two Rare Exon 21 EGFR Mutations in Patients Treated with Gefitinib

Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Relapsing.

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping Ibiayi Dagogo-Jack, MD, Justin.

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies Meghan Campo, MD, David Gerber, MD, Justin F. Gainor, MD, Rebecca S. Heist, MD, MPH, Jennifer S. Temel, MD, Alice T. Shaw, MD, PhD, Panos Fidias, MD, Alona Muzikansky, Jeffrey A. Engelman, MD, PhD, Lecia V. Sequist, MD, MPH Journal of Thoracic Oncology Volume 11, Issue 11, Pages 2022-2026 (November 2016) DOI: 10.1016/j.jtho.2016.06.032 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Individual patient response to treatment. Colored bars represent the magnitude of each patient’s response to afatinib compared with baseline tumor burden with type of EGFR mutation noted. RECIST, Response Evaluation Criteria in Solid Tumors. Journal of Thoracic Oncology 2016 11, 2022-2026DOI: (10.1016/j.jtho.2016.06.032) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 CONSORT diagram. Flow of patients who consented to repeat biopsy. pts, patients; pt, patient; PD, progressive disease; AR, acquired resistance; CNS, central nervous system. Journal of Thoracic Oncology 2016 11, 2022-2026DOI: (10.1016/j.jtho.2016.06.032) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions